The bleb formation of the extracellular pseudopodia; early evidence of microtubule depolymerization by estramustine phosphate in glioma cell; in vitro study
- PMID: 11451201
- DOI: 10.1023/a:1010653613588
The bleb formation of the extracellular pseudopodia; early evidence of microtubule depolymerization by estramustine phosphate in glioma cell; in vitro study
Abstract
Estramustine phosphate (EMP) is an anti-microtubule agent that depolymerizes microtubules and also causes apoptosis of glioma cells. Both of these pharmacological actions have been previously studied within the same cytotoxic range of EMP concentrations. The purpose of this study was to investigate which of these two phenomena occurred before the other. A preliminary MTT assay was done to distinguish non-cytotoxic (0.005-0.1 microM) and cytotoxic (0.5-10 microM) of EMP for BT4C cells. To investigate apoptotic changes, transmission electron microscopy (TEM), DNA laddering, and in situ endo-labeling (TUNEL) method were employed. A chemotaxis assay was used to assess cell motility. Scanning electron microscopy and TEM immunocytochemistry with an anti-beta tubulin antibody were applied to detect morphological changes of the microtubules. Suppression of cell motility by cytotoxic doses of EMP (0.5-10 microM) group was attributed by the cyto-reductive effect, relating to apoptosis. At 0.01-0.1 microM (non-cytotoxic doses), EMP did not indue apoptosis. At these concentrations, TEM and immunohistochemistry revealed the formation of blebs on the tip of the pseudopodia that contained abnormally depolymerized microtubules, a finding that was not observed at a low temperature or during cell migration. Cell chemotaxis was significantly inhibited by cytostatic EMP doses (0.05 and 0.1 microM). Bleb formation of the pseudopodia might be evidence of the abnormal disassembly of microtubules by cytostatic EMP concentrations, prior to the induction of apoptosis. In glioma cells EMP probably initiates apoptosis by causing the depolymerization of microtubules. Inhibition of cell motility by cytostatic doses of EMP could be beneficial to support other therapies.
Similar articles
-
Drug-induced apoptosis by anti-microtubule agent, estramustine phosphate on human malignant glioma cell line, U87MG; in vitro study.J Neurooncol. 2000 Apr;47(2):133-40. doi: 10.1023/a:1006393705560. J Neurooncol. 2000. PMID: 10982154
-
Induction of apoptosis by estramustine phosphate mediated by phosphorylation of bcl-2.J Neurooncol. 2001 Aug;54(1):23-9. doi: 10.1023/a:1012566601485. J Neurooncol. 2001. PMID: 11763419
-
Radiosensitizing effect of estramustine in malignant glioma in vitro and in vivo.J Neurooncol. 1995;23(3):191-200. doi: 10.1007/BF01059950. J Neurooncol. 1995. PMID: 7673981
-
Estramustine-based chemotherapy.Semin Urol Oncol. 1997 Feb;15(1):13-9. Semin Urol Oncol. 1997. PMID: 9050135 Review.
-
Pharmacokinetics and pharmacodynamics of estramustine phosphate.Clin Pharmacokinet. 1998 Feb;34(2):163-72. doi: 10.2165/00003088-199834020-00004. Clin Pharmacokinet. 1998. PMID: 9515186 Review.
Cited by
-
Rat brain tumor models in experimental neuro-oncology: the C6, 9L, T9, RG2, F98, BT4C, RT-2 and CNS-1 gliomas.J Neurooncol. 2009 Sep;94(3):299-312. doi: 10.1007/s11060-009-9875-7. Epub 2009 Apr 21. J Neurooncol. 2009. PMID: 19381449 Free PMC article. Review.
-
Pilot study of estramustine added to radiosurgery and radiotherapy for treatment of high grade glioma.J Neurooncol. 2004 Mar-Apr;67(1-2):215-20. doi: 10.1023/b:neon.0000021825.41221.b5. J Neurooncol. 2004. PMID: 15072470
References
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources